Revamping front-line multi-drug chemotherapy for retinoblastoma to include topotecan helped to maintain high cure rates for the eye cancer while preserving patients’ vision and reducing their risk of treatment-related leukemia. Results of the St. Jude Children’s Research Hospital study appear online today in the Journal of Clinical Oncology.
“I don’t think any good cancer center director would be worth their weight in salt if they weren’t worried about something at night,” said Mark Evers, director of University of Kentucky Markey Cancer Center.
